USANA Health (USJ) AI Stock Analysis

1 Followers

USANA Health

(Frankfurt:USJ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetThe absence of TTM debt and sizable equity base give USANA financial flexibility to fund product, retail, and omnichannel initiatives without relying heavily on lenders. This should improve resilience through operating volatility and preserve options for disciplined investment over the next several quarters.

Negative Factors

Revenue and profitability deteriorationThe sharp revenue contraction and move to a net loss show that USANA's current earnings base has weakened materially. Persistently lower sales can reduce operating leverage, constrain reinvestment, and make the company's historically attractive gross margin less useful unless volumes and cost discipline recover.

USANA Health (USJ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 244.63M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -11.5
Beta (1Y): 0.69
Revenue Growth: -5.93%
EPS Growth: -217.51%
Country: Germany
Employees: 1,570
Sector: Consumer Defensive
Sector Strength: 62
Industry: Packaged Foods

USANA Health Business Overview & Revenue Model

Company Description

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. Th...

USANA Health Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|% Change Since:-10.85%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was described by management as mixed, with meaningful challenges in Core Nutrition active customers, Rise Wellness performance and the reduced adjusted EBITDA outlook. However, the company reported improved Core profitability, a return to growth in Southeast Asia Pacific, accelerating Hiya subscriber and sales momentum, stronger cash generation, expanded retail distribution and continued progress on its omnichannel strategy. Highlights significantly outweighed the lowlights.

Positive Updates

Omnichannel Strategy Supported by Debt-Free Balance Sheet

USANA is evolving from a single-channel direct-selling company into a diversified omnichannel health and wellness company focused on consumer acquisition and loyalty. The company said its debt-free balance sheet provides flexibility to fund this expansion with discipline.

Negative Updates

Core Nutrition Active Customers Declined

Core Nutrition active customers declined 8% year-over-year. Greater China, the company's largest market, accounted for most of the sequential decline in net sales and active customers, and every region outside Southeast Asia Pacific declined in constant currency during the quarter amid lighter incentive and promotional activity.

Company Guidance

For fiscal year 2026, management expects net sales approaching $900 million and adjusted EBITDA of approximately $77 million, compared with the prior outlook of $80.5 million; Hiya’s net sales outlook was raised to $130 million, with sequential growth in net sales and adjusted EBITDA anticipated, while Core Nutritional net sales are assumed at roughly $740 million within the range we provided at the beginning of the year and $10 million below our most recent outlook. Rise’s outlook assumes certain retail orders currently scheduled for the fourth quarter to ship as planned; if their timing shifts into the first quarter, 2026 results could be modestly below the outlook, with changes in net sales and earnings expected to be realized in 2027. Incentive-plan adjustments are expected to roll out throughout 2027, new product launches are expected in 2027, Hiya margins are expected to go up quite substantially in Q4, and Rise expects to be in 4,100 stores by the end of this year, with club expansion beginning in early Q1.

USANA Health Risk Analysis

USANA Health disclosed 43 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

USANA Health Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:USJ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HLF	65Neutral	$1.60B	9.17	-38.70%	―	6.35%	-45.18%
FTLF	63Neutral	$77.95M	12.85	13.98%	―	60.61%	-22.94%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LFVN	54Neutral	$63.92M	23.19	8.17%	3.82%	-24.79%	-73.68%
NATR	53Neutral	$178.14M	12.48	8.76%	―	1.21%	0.20%
NAII	39Underperform	$5.96M	-0.26	-33.23%	―	9.08%	-52.59%

* Consumer Defensive Sector Average

Performance Comparison

DE:USJ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:USJ	USANA Health Sciences Inc	11.50	-4.20	-26.75%
HLF	Herbalife Ltd	15.96	7.16	81.36%
NAII	Natural Alternatives International	0.97	-1.99	-67.36%
NATR	Nature's Sunshine Products	10.36	-10.17	-49.54%
LFVN	LifeVantage Corp	4.97	-1.13	-18.52%
FTLF	Fitlife Brands	8.48	-9.12	-51.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

USANA Health AI Stock Analysis